**Instructions:** Complete staff initials next to procedures completed. If a procedure listed on the checklist is not performed, enter “ND” for “not done” or “NA” for “not applicable” beside the item and record the reason why (if not self-explanatory); initial and date this entry. If any procedures are not conducted on the date recorded above, ensure the date procedure conducted is included in the comments section.

| **Procedure** | **Staff Initials** | **Comments:** |
| --- | --- | --- |
|  | Confirm identity and PTIDs |  |  |
|  | Check for co-enrollment in other studies per site SOPs:* NOT enrolled in another study ⇒ CONTINUE.
* Enrolled in another study ⇒ STOP. Consult the PSRT safety considerations.
 |  |  |
|  | Review elements of informed consent as needed. Explain procedures to be performed at today’s visit. |  |  |
|  | Review/update locator information using site-specific form. |  |  |
|  | Provide available test results from previous visit. Treat and/or refer for care as required. |  |  |
|  | Complete the **Follow-up Visit Y/N CRF** for **MOTHER** and/or **INFANT**\* If exiting at an interim visit, instead add an Interim Visit folder. |  |  |
|  | **MOTHER**: Collect study product from last month’s use as applicable: * N/A no product returned.

**If ring used last month:** * N/A (if not using ring)

Have participant (or clinician/designee) remove used ring. Collect used ring, send to lab for storage, and document on **Participant-Specific Clinic Study Product Accountability Log, and** **Ring Insertion and Removal CRF** **If oral Truvada used last month:*** N/A (if not using oral Truvada)

Collect study oral Truvada bottle with any unused Truvada and send back to pharmacy, if applicable. Document on **Participant-Specific Clinic Study Product Accountability Log,** and **PrEP Provisions and Returns CRF**  |  |  |
|  | **MOTHER:** Complete **Discontinuation of Study Product Log CRF.** Complete Study Product Supply Slip as “Permanent Discontinuation” for the reason of early termination/withdrawal and send to pharmacy. |  |  |
|  | **MOTHER**: collect urine (15-60 mL) and perform tests:* Pregnancy
* Dipstick urinalysis and/or culture per site SOP, ***if indicated***
	+ N/A

Document on **Pregnancy Test Results CRF** and **Urine Test Results CRF, if applicable.** |  |  |
|  | **MOTHER:** Administer **Behavioral Assessment – Month 3 Follow Up CRF** per the participant’s visit number and the product she has been assigned:* Ring
* Tablet

Refer participant to counselor if requested. |  |  |
|  | **MOTHER:** Administer **COVID Behavioral Assessment CRF** |  |  |
|  | **MOTHER:** Administer the **Ring Adherence Y/N, Ring Adherence CRFs** OR **Tablet Adherence Y/N, Tablet Adherence CRFs** per product assignment. |  |  |
|  | **MOTHER:** Administer the **Social Impact Y/N CRF.** Review/update **Social Impact Log CRFs**, as applicable. |  |  |
|  | **MOTHER**: Administer the **Feeding Assessment – Follow-up CRF** and complete the **Feeding Inventory** **CRF**, if applicable. |  |  |
|  | Collect follow-up medical/medications (including medicated vaginal products for mother) history, review pediatric care records and document any AEs; review update:* **Adverse Event Y/N and Adverse Event Log CRFs** for **MOTHER** and **INFANT**
* **Concomitant Medications Y/N and Log CRFs, if applicable** for **MOTHER** and **INFANT**
 |  |  |
|  | **MOTHER**: Administer **Edinburgh Postnatal Depression Scale CRF.** Refer for counseling/support, if needed. If after further clinical assessment, diagnosis of depression and/or other mental health conditions are made, record on the **AE Log**. |  |  |
|  | **MOTHER**: Assess whether the participant has inserted anything in her vagina since her last visit. Document use of non-medicated gels, water, soap, dry materials (such as paper, ashes, or powders), and any other materials inserted vaginally on a **Vaginal Practices CRF**.*Note: all medicated vaginal products (including prescription medications, over-the-counter preparations, vitamins and nutritional supplements, and herbal preparations which are intended to function as medication) should be recorded on the* ***Concomitant Medications Log.*** |  |  |
|  | Provide contraceptive counseling. Document in chart notes and/or on **Contraceptive Counseling Worksheet.** |  |  |
|  | Administer and document HIV pre-testing and HIV/STI risk reduction counseling using the **HIV Pre/Post Test** and **HIV/STI Risk Reduction Counseling Worksheet**. |  |  |
|  | **MOTHER**: Collect the following amounts of blood and send to lab for testing:* HIV-1
	+ [X] mL [color] top [additive] tube
* Plasma for DPV (ring group)
* *N/A (Truvada group).*
	+ 4 mL Purple top (EDTA) tube
* Dried blood spot (DBS) for FTC-TP & TFV-DP (Truvada group)
* *N/A (ring group)*
	+ 4 mL purple top (EDTA) tube
* AST/ALT
	+ [X] mL [color] top [additive/no additive] tube
* Complete blood count (CBC) with platelets
	+ [X] mL [color] top [additive] tube
* Blood creatinine (and calculated creatinine clearance) [weight must be taken for CrCl calculation]
	+ [X] mL [color] top [additive/no additive] tube

***If indicated:**** Syphilis serology
	+ [X] mL [color] top [additive/no additive] tube

Document stored specimen collection on the **Specimen Storage CRF** and **LDMS Specimen Tracking Sheet.** |  |  |
|  | **MOTHER**: Perform and document two rapid HIV test(s) per site SOPs and complete HIV test results and post-testing actions (including referrals if needed/requested per site SOPs):* If both tests negative = UNINFECTED ==> CONTINUE.
* If both tests positive = INFECTED ==> STOP ***or****,*
* If one test positive and one test negative = DISCORDANT ==> STOP. (Refer to MTN-043 HIV Confirmation and Seroconversion Procedure Guide for complete instructions.)

Document test results onto **HIV Test Results CRF** and **HIV Confirmatory Results CRF**, if applicable. |  |  |
|  | * Provide and document HIV post-test counseling using the **HIV Pre/Post Test and HIV/STI Risk Reduction Counseling Worksheet**
* Offer condoms
 |  |  |
|  | Provide PrEP counseling to discuss current local policies and access to PrEP following study exit for interested participants. Document in chart notes. |  |  |
|  | **INFANT:** Collect the following amounts of blood and send to lab for testing:* Plasma for DPV (ring group)
* *N/A (Truvada group).*
	+ 2 mL Purple top (EDTA) tube
* Dried blood spot (DBS) for FTC-TP (Truvada group)
* *N/A (ring group)*
	+ 2 mL purple top (EDTA) tube

Document stored specimen collection on the **Infant Specimen Storage CRF** and **LDMS Specimen Tracking Sheet.**  |  |  |
|  | **MOTHER**: Collect breastmilk sample from mother and prepare for drug level testing. * Have mother fully express milk from one breast by hand or manual pump in to a cup or designated container. Review the Breast Milk Expression Guide.
* In the presence of the mother, swirl the sample to mix and transfer 2 ml each into 4 cryovials (8mL total) and send to lab.
* Offer any leftover milk to the mother in a sealed container.
	+ If mother keeps leftover milk, review the Expressed Milk Factsheet.
	+ Dispose of milk in presence of mother if she declines the leftover milk, per site practices.

Document sample collection on the **Specimen Storage CRF** and **LDMS Specimen Tracking Sheet.** |  |  |
|  | **MOTHER**: perform and document targeted physical exam. Complete **Vital Signs CRF** and **Physical Examination CRF**. |  |  |
|  | **MOTHER**: perform and document a pelvic exam and sample collection per the *Pelvic Exam Checklist*. Document on **Pelvic Exam Diagrams** and **Pelvic Exam CRF.** |  |  |
|  | **INFANT:** perform targeted physical exam and complete **Infant Vital Signs CRF** and **Physical Examination CRF.** |  |  |
|  | Administer the appropriate **Ages and Stages Questionnaire** and complete **Infant Ages and Stages Assessment CRF** for **INFANT** |  |  |
|  | Evaluate findings identified during pelvic and physical examinations and/or medical history review. Document in chart notes and update **Concomitant Medications Log, AE Y/N and Log** **CRFs**, if applicable, and document ongoing conditions on **AE Log** for **MOTHER** and **INFANT.** |  |  |
|  | Provide and explain all available findings and results to participant. Refer for other findings as indicated. ***If indicated****,* treat for STI/RTI/UTI per site SOP. |  |  |
|  | Complete **Study Termination CRF** |  |  |
|  | Complete Permission to Contact Log [and or sites specific tool]. *For pregnant participants:* As indicated per protocol, confirm permission to contact participant upon pregnancy outcome and at the infant’s 1-year birthday, if born alive, to capture outcome information after study exit (tick all that apply): * Participant permits contact upon pregnancy outcome and infant’s 1-year birthday for outcome information after study exit
* Participant permits capture of outcome information for pregnancy and infant from medical records
* **No,** participant does not permit any contact or capture of outcome information after study exit

Note: Contacts after study termination should be documented in the chart notes only with the exception of completion of the Pregnancy Outcome CRF and 1-Year Infant Assessment CRF, if termination was due to a pregnancy. Do not update any AE CRFs after participant termination.  |  |  |
|  | Document reason for early termination in chart notes.  |  |  |
|  | Complete the **Follow-up Visit Summary CRF** for **MOTHER** and **Infant Follow-up Visit Summary CRF INFANT,** or **Interim Visit Summary CRF**, as applicable. |  |  |
|  | Perform QC1: while participant is still present, review the following for completion and clear documentation (for both mother and infant unless otherwise noted):* **LDMS Specimen Tracking Sheet**, **Specimen Storage CRF**
* **AE Logs, Vaginal Practices (mother), Concomitant Medications Logs** to ensure all conditions, medications, AEs are captured consistently and updated.
* **Edinburgh Postnatal Depression Scale CRF (Mother)**
* **Infant Ages and Stages CRF (Infant)**
* **Behavioral Assessment, Ring/Tablet Adherence, COVID Behavioral Assessment, Social Impacts CRFs (mother)**
* **Feeding Assessment/Inventory (Mother)**
* **Chart notes**
 |  |  |
|  | Provide reimbursement. |  |  |
|  | Perform QC2 review and ensure that data is entered in Medidata for the following CRFs/forms:**MOTHER**Required CRFs* Follow-up Visit Y/N, Follow-up Visit Summary
* Specimen Storage
* Feeding Assessment – Follow-up
* Edinburgh Postnatal Depression Scale
* Social Impacts
* Behavioral Assessment– Month 3 Follow Up
* COVID Behavioral Assessment
* Ring Adherence Y/N, Ring Adherence or Tablet Adherence Y/N, Tablet Adherence *(per participant’s study arm)*
* HIV Test Results
* Pregnancy Test Results
* Hematology \*
* Chemistry Panel\*
* Vital Signs
* Physical Examination
* Pelvic Exam
* Ring Insertion and Removal, or PrEP Provisions and Returns *(per participant’s study arm)*
* *Study Termination*

*As needed* * HIV Confirmatory Results
* Adverse Events Log
* Concomitant Medications Log
* STI Test Results\*
* Vaginal Practices
* Urine Test Results\*
* IDI Tracking
* Discontinuation of Study Product

Paper Forms:* LDMS Specimen Tracking Sheet
* HIV Pre-/Post-Test and HIV/STI Risk Counseling Worksheet
* Contraceptive Counseling Worksheet
* Participant-Specific Clinic Study Product Accountability Log
* Pelvic Exam Diagrams

**INFANT**Required CRFs* Follow-up Visit Y/N, Infant Follow-up Visit Summary
* Infant Specimen Storage
* Physical Examination
* Infant Vital Signs
* Infant Ages and Stages Assessment

*As needed** Concomitant Medications YN/Log (if medications are reported)
* Adverse Events log (if AEs reported)

Paper form: * Ages and Stages Questionnaire

*\*CRFs/Tools to be completed when lab results are available* |  |  |